Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. BioVersys AG's Goodwill for the quarter that ended in Dec. 2025 was CHF0.00 Mil. BioVersys AG's Total Assets for the quarter that ended in Dec. 2025 was CHF90.64 Mil.
Therefore, BioVersys AG's Goodwill to Asset Ratio for the quarter that ended in Dec. 2025 was 0.00.
BioVersys AG (XSWX:BIOV) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
BioVersys AG Goodwill-to-Asset Related Terms
BioVersys AG Goodwill-to-Asset Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Goodwill-to-Asset Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Goodwill-to-Asset
0.00
0.00
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Goodwill-to-Asset
0.00
0.00
0.00
0.00
XSWX:BIOV vs VRTX, REGN, RVMD: Goodwill-to-Asset Comparison
For the Biotechnology subindustry, BioVersys AG's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Goodwill-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Goodwill-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a Goodwill-to-Asset of 0.00 as of Dec. 2025. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Goodwill-to-Asset too high?
BioVersys AG's current Goodwill-to-Asset is 0.00. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Goodwill-to-Asset compare to VRTX and REGN?
BioVersys AG's Goodwill-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on BioVersys AG and its competitors. BioVersys AG's current Goodwill-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Goodwill-to-Asset of 0.00. The current Goodwill-to-Asset is 0.00. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Goodwill-to-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
